Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

information fournie par Boursorama •08/09/2015 à 19:00

Data confirm strength of previously reported results

Strasbourg, France, September 8, 2015 - Transgene SA (Euronext: TNG) today announced the presentation by Dr. Elisabeth Quoix of final data from the Phase 2b part of the TIME trial with TG4010 MUC1 targeted immunotherapy in non-small cell lung cancer (NSCLC) at the 16th World Conference on Lung Cancer in Denver, CO, USA.

The overall survival (OS) data confirm the strength of previously reported improvements and are significant in patients with a "low" level of triple positive activated lymphocytes (TrPAL ), as well as in those patients with low TrPAL and non-squamous disease.

Elisabeth Quoix, M.D., Head of the Department of Pulmonology at the University Hospital of Strasbourg and Coordinating Investigator of the TIME study, said: "Lung cancer remains a devastating disease and there is an urgent need for new treatments. Immunotherapies are an area of great promise, and I look forward to the further development of TG4010 in combination with chemotherapy, as well as with immune checkpoint inhibitors, in this important indication."